Loading
PET scans built from radiolabelled antibodies or their fragments, to see any protein an antibody can reach, including immune cells inside tumours.
Immuno-PET attaches long-lived positron emitters such as 89Zr or 64Cu to antibodies, minibodies or nanobodies, so that any protein an antibody can reach can be imaged across the whole body. It covers 89Zr-antibody imaging of ADC targets including TROP2 and HER2, and T-cell imaging with 89Zr-crefmirlimab berdoxam, a CD8 minibody, and 18F-AraG, which marks activated T cells. CD8 PET is in phase 2/3 as a pharmacodynamic and predictive biomarker for checkpoint inhibitors, aiming to show whether T cells are entering tumours early in treatment. The strengths are non-invasive imaging of target and immune infiltrate, and the fact that any antibody can be turned into a tracer. Full antibodies have slow kinetics, requiring days before imaging, and 89Zr is costly. Immuno-PET turns therapeutic antibodies into imaging agents that show where their targets and the immune cells are.
Long-lived positron emitters (89Zr, 64Cu) chelated to antibodies, minibodies, or nanobodies.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Zirconium-89 girentuximab is Telix's PET scan that tells whether a kidney mass is clear cell renal cell carcinoma without a biopsy; the phase 3 ZIRCON trial met its endpoints in 2023 and the product is under regulatory review.
Query for this technology: (TITLE:"immuno-PET" OR ABSTRACT:"immuno-PET" OR TITLE:"immunoPET" OR ABSTRACT:"immunoPET" OR TITLE:"CD8 PET" OR ABSTRACT:"CD8 PET" OR TITLE:"89Zr-labeled antibody" OR ABSTRACT:"89Zr-labeled antibody"). Results are unfiltered search hits about Immuno-PET, not a curated reading list.
Shares Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET, TROP2 PET to choose and sequence TROP2 ADCs, TROP2 PET, TROP2.
Shares HER2 PET, PET (positron emission tomography), PET/CT, HER2.
Shares Zirconium-89 girentuximab, 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study, CAIX PET (89Zr-girentuximab).
Shares No one can predict who responds to immunotherapy, PD-L1, PD-1, Melanoma.
Shares CD8 PET to stop or switch immunotherapy early, No one can predict who responds to immunotherapy, Melanoma, Non-small-cell lung cancer.
Shares No one can predict who responds to immunotherapy, Monoclonal antibodies, Melanoma, Non-small-cell lung cancer.